877. North American Phase 3/3b Experience with Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes

BACKGROUND: Cabotegravir (CAB) plus rilpivirine (RPV) is the first complete long-acting (LA) regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. CAB+RPV LA dosed every 4 weeks (Q4W) or every 8 weeks (Q8W) demonstrated noninferior efficacy in multinational...

Descripción completa

Detalles Bibliográficos
Autores principales: Taiwo, Babafemi O, Tan, Darrell, Patel, Parul, Teichner, Paula, Polli, Joseph, Garside, Louise, D’Amico, Ronald, Talarico, Christine L, Van Solingen-Ristea, Rodica, Baugh, Bryan, Spreen, William, Aboud, Michael, Bosse, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644679/
http://dx.doi.org/10.1093/ofid/ofab466.1072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644679/
http://dx.doi.org/10.1093/ofid/ofab466.1072

Ejemplares similares